Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220802276> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4220802276 endingPage "82" @default.
- W4220802276 startingPage "76" @default.
- W4220802276 abstract "This study aimed to characterize current treatment patterns and healthcare resource utilization (HRU) observed among patients with hepatocellular carcinoma (HCC) after the failure of sorafenib in real-world setting in Taiwan.A chart review was conducted in 130 patients; the inclusion criteria were patients with HCC who were aged 20 years or older and had received systemic therapy or best supportive care after failure of first-line systemic treatment with sorafenib between 2016 and 2018. Anonymized data on patient characteristics, treatment pathways, and survival were abstracted.The mean age of patients was 61.7 years (range 27-84); of these 130 patients, 103 (79%) were male, 81 (62%) had high alpha-fetoprotein (AFP) levels (≥400 ng/mL), and 96 (78.0%) were deceased at the time of data abstraction. After sorafenib therapy, 60 patients (46%) received systemic therapy, including nivolumab monotherapy (42%) and chemotherapy (25%). Oncologist visits at a semiannual per-patient rate of 3.7 (95% confidence interval [CI] 3.4-4.0) and hospitalizations at rate of 1.1 (95% CI 1.0-1.3) were the key contributors to HRU. Semiannual per-patient hospitalization rate was 1.3 (95% CI 1.1-1.5) in the high-AFP group. Median survival from discontinuation of sorafenib was 6.9 months (95% CI 5.9-9.0).This real-world evidence research on treatment patterns reflected substantial HRU consistent with the severity of HCC, particularly in the high-AFP group. Findings highlighted continuing high mortality in HCC, underlying a need for new treatments that can lengthen survival. Results can inform future evaluations of new HCC treatments that estimate the health economic impact of their adoption in Taiwan." @default.
- W4220802276 created "2022-04-03" @default.
- W4220802276 creator A5000216315 @default.
- W4220802276 creator A5002095623 @default.
- W4220802276 creator A5004380370 @default.
- W4220802276 creator A5016157974 @default.
- W4220802276 creator A5038677051 @default.
- W4220802276 creator A5053927522 @default.
- W4220802276 creator A5079982273 @default.
- W4220802276 date "2022-07-01" @default.
- W4220802276 modified "2023-10-01" @default.
- W4220802276 title "Treatment Patterns and Health Resource Utilization in Patients With Hepatocellular Carcinoma After Failure of Sorafenib in Real-World Setting in Taiwan" @default.
- W4220802276 cites W2277004004 @default.
- W4220802276 cites W2290774643 @default.
- W4220802276 cites W2560499218 @default.
- W4220802276 cites W2625856057 @default.
- W4220802276 cites W2766032799 @default.
- W4220802276 cites W2796067155 @default.
- W4220802276 cites W2809889937 @default.
- W4220802276 cites W2941974000 @default.
- W4220802276 cites W2990602950 @default.
- W4220802276 cites W2996666721 @default.
- W4220802276 cites W3021985029 @default.
- W4220802276 doi "https://doi.org/10.1016/j.vhri.2022.01.001" @default.
- W4220802276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35278836" @default.
- W4220802276 hasPublicationYear "2022" @default.
- W4220802276 type Work @default.
- W4220802276 citedByCount "0" @default.
- W4220802276 crossrefType "journal-article" @default.
- W4220802276 hasAuthorship W4220802276A5000216315 @default.
- W4220802276 hasAuthorship W4220802276A5002095623 @default.
- W4220802276 hasAuthorship W4220802276A5004380370 @default.
- W4220802276 hasAuthorship W4220802276A5016157974 @default.
- W4220802276 hasAuthorship W4220802276A5038677051 @default.
- W4220802276 hasAuthorship W4220802276A5053927522 @default.
- W4220802276 hasAuthorship W4220802276A5079982273 @default.
- W4220802276 hasBestOaLocation W42208022761 @default.
- W4220802276 hasConcept C121608353 @default.
- W4220802276 hasConcept C126322002 @default.
- W4220802276 hasConcept C143998085 @default.
- W4220802276 hasConcept C177713679 @default.
- W4220802276 hasConcept C2777701055 @default.
- W4220802276 hasConcept C2778019345 @default.
- W4220802276 hasConcept C2778695046 @default.
- W4220802276 hasConcept C2778715236 @default.
- W4220802276 hasConcept C2780030458 @default.
- W4220802276 hasConcept C44249647 @default.
- W4220802276 hasConcept C71924100 @default.
- W4220802276 hasConceptScore W4220802276C121608353 @default.
- W4220802276 hasConceptScore W4220802276C126322002 @default.
- W4220802276 hasConceptScore W4220802276C143998085 @default.
- W4220802276 hasConceptScore W4220802276C177713679 @default.
- W4220802276 hasConceptScore W4220802276C2777701055 @default.
- W4220802276 hasConceptScore W4220802276C2778019345 @default.
- W4220802276 hasConceptScore W4220802276C2778695046 @default.
- W4220802276 hasConceptScore W4220802276C2778715236 @default.
- W4220802276 hasConceptScore W4220802276C2780030458 @default.
- W4220802276 hasConceptScore W4220802276C44249647 @default.
- W4220802276 hasConceptScore W4220802276C71924100 @default.
- W4220802276 hasLocation W42208022761 @default.
- W4220802276 hasLocation W42208022762 @default.
- W4220802276 hasOpenAccess W4220802276 @default.
- W4220802276 hasPrimaryLocation W42208022761 @default.
- W4220802276 hasRelatedWork W1964466002 @default.
- W4220802276 hasRelatedWork W2043470781 @default.
- W4220802276 hasRelatedWork W2318402467 @default.
- W4220802276 hasRelatedWork W2911992161 @default.
- W4220802276 hasRelatedWork W2947531202 @default.
- W4220802276 hasRelatedWork W3004563436 @default.
- W4220802276 hasRelatedWork W3024283902 @default.
- W4220802276 hasRelatedWork W4220997720 @default.
- W4220802276 hasRelatedWork W4253087965 @default.
- W4220802276 hasRelatedWork W66886536 @default.
- W4220802276 hasVolume "30" @default.
- W4220802276 isParatext "false" @default.
- W4220802276 isRetracted "false" @default.
- W4220802276 workType "article" @default.